IUPAC: 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)ethoxy]ethanol · C21H25N3O2S · MW 383.51 g/mol · CAS 111974-69-7 · ChEMBL716
Quetiapine (Seroquel, ICI-204,636). Dibenzothiazepine atypical antipsychotic — a broad, dirty, promiscuous receptor blocker whose clinical identity changes with dose. A fast-off D2 antagonist with 5-HT2A blockade and unusually high H1 affinity, plus an active metabolite (norquetiapine) that adds a norepinephrine-transporter / 5-HT1A antidepressant arm. Trade/context names: Seroquel XR, "Suzie-Q", "quell", "baby heroin".
Quetiapine is a promiscuous GPCR antagonist, not a transporter drug. It blocks a wide panel of aminergic receptors — D2, 5-HT2A, 5-HT2C, H1, α1, α2, 5-HT1A — but the number that defines its clinical behaviour is not a Ki at all: it is the dissociation rate (koff) at D2. Quetiapine (with clozapine) sits at the extreme "loose, fast-off" end of the antipsychotic spectrum. It occupies the D2 orthosteric pocket only transiently, so at any instant a fraction of striatal D2 is blocked and endogenous dopamine easily re-competes.
This is the Kapur–Seeman "fast-dissociation" model of atypicality made literal: enough transient D2 blockade to be antipsychotic at high doses, but not the sustained, tight occupancy that drives extrapyramidal symptoms (EPS), hyperprolactinemia and tardive dyskinesia. Clinical PET shows quetiapine produces only ~30% peak striatal D2 occupancy even at therapeutic doses — below the ~60–70% "antipsychotic threshold" and far below the ~80% "EPS threshold" — with occupancy decaying to near-baseline within hours. Low, loose, and leaky by design.
Binds the D2 orthosteric pocket (Ki ~180 nM) but releases fast (high koff). Transient mesolimbic blockade blunts positive psychotic symptoms at high dose; rapid dissociation spares nigrostriatal D2 → very low EPS and near-zero prolactin elevation.
Blockade of cortical/striatal 5-HT2A (Ki ~220 nM) disinhibits nigrostriatal dopamine, further protecting against motor side effects and contributing to the "atypical" profile alongside 5-HT2C block.
The highest-affinity target on the panel (Ki ~8.7 nM). Deep histaminergic blockade is the pharmacological basis of the profound sedation seen even at sub-therapeutic (25–50 mg) doses — and of the appetite/weight liability.
Potent α1 blockade (α1B Ki ~13.6 nM) drives orthostatic hypotension, dizziness and reflex tachycardia. α2 antagonism (Ki ~87 nM) may add a modest noradrenergic/antidepressant nudge.
The N-dealkyl metabolite is a NET inhibitor (Ki ~35 nM) and 5-HT1A partial agonist. This is a genuinely different pharmacology bolted onto the parent — the mechanistic root of quetiapine's antidepressant licence.
Parent quetiapine is a weak-to-moderate M1 antagonist (Ki ~56–120 nM); norquetiapine is more potent muscarinic. Contributes dry mouth, constipation, and cognitive dulling, plus cholinergic-rebound on abrupt stop.
The takeaway: quetiapine's "antipsychotic" label undersells what the receptor pharmacology actually says. It is a histamine blocker first (by affinity), an adrenergic and serotonergic blocker second, and a D2 antagonist only weakly and transiently. Which of these dominates is entirely a function of how much you give — the subject of Section 03.
Quetiapine is rapidly absorbed (Tmax ~1–1.5 h for immediate-release; ~6 h for the XR matrix) and extensively metabolised in the liver, chiefly by CYP3A4. The parent has a short elimination half-life (~6–7 h), which is why immediate-release dosing is typically twice daily and why the effect of a low bedtime dose is largely gone by morning — a big part of its appeal, and its problem, as an off-label hypnotic. Less than 1% is excreted unchanged; clearance is metabolism-limited.
Metabolism cascade: Two CYP3A4-dominated routes diverge from the parent — an activating N-dealkylation and an inactivating sulfoxidation.
Norquetiapine (N-desalkylquetiapine, marked ★) is the pharmacologically important metabolite. Unlike the parent it is a potent norepinephrine transporter (NET) inhibitor and a 5-HT1A partial agonist — the mechanistic basis for quetiapine's efficacy in bipolar depression and adjunctive major depression. Because it is generated downstream of the parent and has a longer half-life, its contribution grows with sustained, higher-dose exposure — the reason antidepressant effect emerges in the middle of the dose range rather than at hypnotic doses.
CYP3A4 is the choke point. Strong inhibitors (ketoconazole, clarithromycin, ritonavir, grapefruit) can raise quetiapine exposure several-fold; strong inducers (carbamazepine, phenytoin, rifampin, St John's wort) can collapse it. Dose adjustment is expected when either is co-administered. Quetiapine itself is a weak enzyme perturber and rarely the perpetrator.
Quetiapine is the clearest example in psychiatry of a drug whose identity is set by dose, because different receptors saturate at different plasma concentrations. Reading the affinity table from tightest to loosest binding is reading the dose–response curve: H1 and α1 engage first, the norquetiapine/monoamine arm next, and D2 only once you push the dose.
At these doses only the highest-affinity targets — H1 (Ki ~8.7 nM) and α1 — are meaningfully occupied. D2 occupancy is negligible. The clinical picture is pure antihistamine sedation with orthostasis: this is the pharmacology behind the enormous off-label use of "25 of Seroquel for sleep." It is not, at this dose, acting as an antipsychotic or a mood stabiliser in any mechanistic sense.
As exposure rises, norquetiapine accumulates to concentrations where NET inhibition (Ki ~35 nM) and 5-HT1A partial agonism become pharmacologically active, while 5-HT2A/5-HT2C blockade adds disinhibition of cortical dopamine and noradrenaline. This is the licensed range for bipolar depression and adjunctive MDD — quetiapine behaving like an atypical antidepressant, not an antipsychotic.
Only here does transient striatal D2 occupancy climb toward the ~60% antipsychotic threshold — and even then it is leaky and short-lived because of the fast koff. This is the range for schizophrenia and acute mania. The same fast dissociation that makes high-dose quetiapine tolerable (low EPS, low prolactin) also makes it a comparatively weak antipsychotic milligram-for-milligram versus tight binders like haloperidol or risperidone.
Because low-dose quetiapine is a reliable sedative, it became one of the most-prescribed off-label hypnotics in the world — for insomnia, anxiety, agitation, and in correctional and dementia settings — despite no robust randomised evidence of hypnotic efficacy at 25–50 mg and a real cardiometabolic price. Multiple guidelines and Choosing Wisely campaigns explicitly recommend against routine quetiapine-for-sleep: you are exposing a patient to weight gain, dyslipidaemia, orthostasis and QT risk to buy a sedative effect achievable with far safer agents. Section 04 covers the harm ledger.
Evidence-based, non-moralistic. Quetiapine is a prescription drug with a real safety ledger — most of the risk is metabolic and cardiovascular, is dose- and duration-dependent, and is compounded when it is used casually as a sleep aid or misused for its sedation.
Quetiapine is a natural case study for the Shannon-entropy / conformational-entropy lens behind FlexAID∆S. Binding free energy decomposes as ΔG = ΔH − TΔSconf − TΔSvib. Tight, slow-off antagonists like haloperidol bury a rigid pharmacophore deep in the D2 pocket, forming a dense hydrogen-bond/salt-bridge network with Asp3.32 and the aromatic cage. That enthalpic anchoring is bought at a steep entropic price: the flexible ligand and several pocket side chains are frozen into one microstate — a large collapse in configurational entropy. A large collapse means a deep, narrow well, a small koff, and long residence time.
Quetiapine sits at the opposite corner. Its dibenzothiazepine tricycle is bent (butterfly geometry) and its piperazine-ethoxy-ethanol tail is long and floppy. It does not fully commit that tail to a single bound conformation, and it forms a shallower contact set. In entropy terms the bound state retains residual conformational freedom — the ligand and the pocket sample more microstates while docked, so the entropy collapse on binding is smaller. A smaller ΔS penalty and a weaker ΔH anchor give exactly what the kinetics show: a shallow well, a high koff, short residence, and only transient occupancy.
The clinical signature of "atypicality" is therefore, at bottom, a thermodynamic choice: quetiapine never fully pays the entropy price required to lock D2 shut, so it lets go quickly and spares the nigrostriatal pathway. The same loose, high-entropy binding mode that keeps motor side effects low is why milligram potency at D2 is modest — and why the drug's other, tighter-binding targets (H1 first) dominate the low-dose experience. Residence time, not affinity alone, is the variable that maps onto the side-effect profile.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
H1
Histamine H1 receptor
|
Ki = 8.7 nM
highest affinity
|
Inverse agonist | |
|
α1B
Alpha-1B adrenergic receptor
|
Ki = 13.6 nM
|
Antagonist | |
|
α2
Alpha-2 adrenergic receptor
|
Ki = 87 nM
|
Antagonist | |
|
D2
Dopamine D2 receptor (DRD2)
|
Ki = 180 nM
loose · fast koff
|
Antagonist | |
|
5-HT2A
Serotonin 2A receptor (HTR2A)
|
Ki = 220 nM
|
Antagonist | |
|
5-HT1A
Serotonin 1A receptor
|
Ki = 230 nM
|
Partial agonist* | |
|
M1
Muscarinic ACh receptor M1
|
Ki = 56 nM
|
Antagonist | |
|
5-HT2C
Serotonin 2C receptor
|
Ki = 1,400 nM
|
Antagonist | |
|
NET
Norepinephrine transporter · norquetiapine
|
Ki ≈ 35 nM
metabolite, not parent
|
Inhibitor |